MedPath

An Open-Label, Expanded Access Program with Nivolumab (ONO-4538) for cancer of unknown primary (CUP) (NivoCUP-2) Biomarker study (WJOG14620MTR)

Not Applicable
Conditions
Cancer of unknown primary
Registration Number
JPRN-UMIN000044038
Lead Sponsor
West Japan Oncology Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
49
Inclusion Criteria

Not provided

Exclusion Criteria

None

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate exploratory biomarkers of nivolumab efficacy for unknown primary cancer.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath